We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Radcal IBA  Group

Download Mobile App




Gene-Based Lymph-Node Assay Guides Breast Surgery

By HospiMedica staff writers
Posted on 13 Nov 2006
An intra-operative, gene-based diagnostic test that detects the spread of breast cancer to the lymph nodes has been launched in Europe.

Using real time-reverse transcriptase polymerase chain reaction (RT-PCR) technology, the test detects genes that indicate metastasis of breast cells in the lymph node. More...
This genetic technology provides a rapid, standardized, objective result, reducing errors and improving reproducibility. The test can easily be performed by trained laboratory technicians, offering advantages to hospitals where pathologists are very busy or are not available.

The in vitro diagnostic test detects clinically relevant (0.2 mm) metastases in sentinel lymph node tissue removed from the breast cancer patient. Test results are reported within 30 to 40 minutes from the time the sentinel nodes are removed, versus a two-to-three day wait for results from current permanent section histology. Results from the test can be used to guide the decision to excise additional lymph nodes and to aid in patient staging. If there is no evidence of cancer in the sentinel node, it is highly unlikely that the cancer has spread to other nodes, and there may be no need for further surgery.

The CE-marked GeneSearch breast lymph node (BLN) test developed by Veridex (Warren, NJ, USA) offers an advanced alternative to more-conventional tissue pathology. The test can be performed intra-operatively and will help pathologists provide surgeons with accurate information to help them determine whether they need to perform a simple lumpectomy or a more complex axillary lymph node dissection.

Mark Myslinski, general manager of Veridex said, "By using molecular biology to guide surgeons in the operating room, second surgeries can be prevented. We believe that the combined benefits of this test--improved patient outcomes and lowered healthcare costs--underscore its value to the medical community.”

Veridex, a Johnson & Johnson company, develops cancer diagnostic products that enable earlier disease detection as well as more accurate staging, monitoring, and therapeutic selection. The company's two complementary product lines are CellSearch assays that identify, enumerate, and characterize circulating tumor cells directly from whole blood, and GeneSearch assays that use molecular technology to diagnose, stage, and more accurately characterize tumors.



Related Links:
Veridex

Platinum Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Gold Member
Heavy-Duty Wheelchair Scale
6495 Stationary
Pulmonary Ventilator
OXYMAG
Xenon Light Source
CLV-S400
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: Professor Bumsoo Han and postdoctoral researcher Sae Rome Choi of Illinois co-authored a study on using DNA origami to enhance imaging of dense pancreatic tissue (Photo courtesy of Fred Zwicky/University of Illinois Urbana-Champaign)

DNA Origami Improves Imaging of Dense Pancreatic Tissue for Cancer Detection and Treatment

One of the challenges of fighting pancreatic cancer is finding ways to penetrate the organ’s dense tissue to define the margins between malignant and normal tissue. Now, a new study uses DNA origami structures... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.